<DOC>
	<DOCNO>NCT01624233</DOCNO>
	<brief_summary>This study ass safety efficacy ixekizumab participant moderate severe psoriasis Japan .</brief_summary>
	<brief_title>A Study Japanese Participants With Moderate-to-Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Men must agree use reliable method birth control study Women must agree use birth control remain abstinent study least 12 week stop treatment Candidates phototherapy and/or systemic therapy Present chronic psoriasis base confirm psoriasis diagnosis least 6 month prior enrollment At least 10 % Body Surface Area ( BSA ) Psoriasis screen enrollment participant plaque psoriasis Static Physician Global Assessment ( sPGA ) score least 3 Psoriasis Area Severity Index ( PASI ) score least 12 screen enrollment participant plaque psoriasis History druginduced psoriasis Concurrent recent use biologic agent Received systemic psoriasis therapy [ psoralen ultraviolet A ( PUVA ) light therapy ] phototherapy within previous 4 week ; topical psoriasis treatment within previous 2 week prior enrollment participant plaque psoriasis Can avoid excessive sun exposure use tan booth least 4 week prior enrollment study Have participate study interleukin17 ( IL17 ) antagonist , include ixekizumab Serious disorder illness psoriasis Serious infection within last 3 month Breastfeeding nursing ( lactate ) woman Clinically significant flare psoriasis 12 week prior enrollment participant plaque psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>